Dernières nouvelles pour 10x Genomics (NASDAQ:TXG) Stock

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

S&P/TSX GlbMn US

S&P/TSX Global Gold Index (USD)

S&P/TSX Global Gold Index (USD) (TR)

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) with a Buy and maintains $37 price target.

News

Price Target

Reiteration

Analyst Ratings

PHAR

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Morgan Stanley analyst Michael Cyprys maintains Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) with a Overweight and raises the price target from $11 to $14.

BRDG

Morgan Stanley Maintains Overweight on Bridge Investment Group, Raises Price Target to $14

Morgan Stanley analyst Michael Cyprys maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Overweight and raises the price target from $164 to $177.

Morgan Stanley Maintains Overweight on Blackstone, Raises Price Target to $177

<h3>Gainers</h3>
<ul>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares increased by 62.2% to $1.16 during Thursday's regular session. The market value of their outstanding shares is at $15.5 million. </li>
<li>Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock rose 14.97% to $23.65. The company's market cap stands at $4.7 billion. </li>
<li>Sify Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares rose 12.79% to $2.91. The company's market cap stands at $1.2 billion. </li>
<li>CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) shares rose 11.22% to $2.08. The market value of their outstanding shares is at $113.5 million. </li>
<li>Fangdd Network Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) stock moved upwards by 8.23% to $1.91. The company's market cap stands at $15.3 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 8.18% to $0.7. The company's market cap stands at $8.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>9F (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) shares declined by 16.6% to $1.81 during Thursday's regular session. The company's market cap stands at $21.3 million. </li>
<li>36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) shares fell 11.54% to $4.68. The company's market cap stands at $182.5 million. </li>
<li>Reading Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDIB#NASDAQ">RDIB</a>) stock decreased by 9.99% to $6.67. The market value of their outstanding shares is at $149.5 million. </li>
<li>MultiMetaVerse Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) stock decreased by 7.45% to $0.46. The company's market cap stands at $15.2 million. </li>
<li>LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) stock fell 7.25% to $0.69. The market value of their outstanding shares is at $68.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEHL

BLMZ

CURI

KRKR

Eaton Vance Massachusetts Municipal Income Trust

RDIB

SIFY

11 Communication Services Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.0% to $0.65 during Thursday's regular session. The market value of their outstanding shares is at $11.2 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares increased by 18.88% to $2.14. The company's market cap stands at $5.5 million. </li>
<li>NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) stock increased by 17.65% to $2.82. The market value of their outstanding shares is at $17.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.01% to $1.41. The company's market cap stands at $84.8 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares increased by 15.81% to $6.5. The company's market cap stands at $118.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 13.69% to $5.98. The company's market cap stands at $77.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 64.2% to $0.07 during Thursday's regular session. The market value of their outstanding shares is at $8.3 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock fell 25.21% to $15.57. The company's market cap stands at $1.8 billion. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 21.17% to $0.4. The market value of their outstanding shares is at $2.2 million. </li>
<li>ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) stock declined by 19.46% to $16.37. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares decreased by 17.78% to $1.11. The company's market cap stands at $27.9 million. </li>
<li>Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) stock fell 17.27% to $7.81. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

GNTA

GRTS

HCTI

INDV

NXGL

RNAZ

Tempest Therapeutics, Inc. - Common Stock

TPST

VCNX

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares moved upwards by 95.5% to $0.18 during Thursday's regular session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares moved upwards by 32.46% to $10.2. The market value of their outstanding shares is at $181.0 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) shares rose 31.36% to $3.06. The market value of their outstanding shares is at $39.2 million. </li>
<li>GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) shares moved upwards by 14.48% to $58.27. The company's market cap stands at $6.9 billion. </li>
<li>Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares increased by 14.18% to $26.54. The company's market cap stands at $2.7 billion. </li>
<li>Turbo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURB#NASDAQ">TURB</a>) stock moved upwards by 13.47% to $2.87. The market value of their outstanding shares is at $31.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 26.8% to $0.78 during Thursday's regular session. The market value of their outstanding shares is at $19.8 million. </li>
<li>JVSPAC Acquisition Corp. - Right (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSAR#NASDAQ">JVSAR</a>) stock declined by 16.97% to $0.27. </li>
<li>Nature's Miracle Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) shares declined by 12.59% to $0.17. The company's market cap stands at $5.3 million. </li>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) shares decreased by 8.68% to $0.23. The market value of their outstanding shares is at $11.1 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) shares declined by 8.46% to $8.01. The market value of their outstanding shares is at $122.3 million. </li>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares decreased by 7.99% to $0.43. The market value of their outstanding shares is at $6.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GLXG

GRFX

JTAI

JVSAR

LASE

MNTS

NMHI

SPPL

SRFM

TURB

12 Industrials Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares moved upwards by 41.9% to $0.36 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock increased by 11.96% to $1.88. The company's market cap stands at $44.8 million. </li>
<li>Akoustis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) stock increased by 10.8% to $0.08. The market value of their outstanding shares is at $8.7 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock moved upwards by 10.7% to $3.93. The market value of their outstanding shares is at $44.5 million. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) stock increased by 10.37% to $2.98. The company's market cap stands at $359.7 million. </li>
<li>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) stock increased by 10.21% to $3.56. The market value of their outstanding shares is at $98.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock declined by 25.8% to $0.53 during Thursday's regular session. </li>
<li>E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) stock declined by 18.88% to $3.31. The company's market cap stands at $1.0 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) stock decreased by 14.82% to $5.52. The market value of their outstanding shares is at $402.8 million. </li>
<li>NiSun Intl Enterprise Dev (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) shares declined by 12.23% to $12.49. The company's market cap stands at $49.3 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) stock declined by 11.43% to $1.86. The market value of their outstanding shares is at $22.1 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock declined by 11.35% to $0.78. The market value of their outstanding shares is at $76.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIXI

AKTS

ATOM

CETX

ETWO

LWLG

MLGO

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NISN

PHUN

WETH

12 Information Technology Stocks Moving In Thursday's Intraday Session

Morgan Stanley analyst Michael Cyprys maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Equal-Weight and raises the price target from $136 to $162.

ARES

Morgan Stanley Maintains Equal-Weight on Ares Management, Raises Price Target to $162

<a href="https://www.youtube.com/watch?v=vJ8aEO6ggOs" title="https://www.youtube.com/watch?v=vJ8aEO6ggOs">https://www.youtube.com/watch?v=vJ8aEO6ggOs</a>

AMD Executive Launches New MI325X AI Chip

<h4>Key Takeaways:</h4>
<ul>
<li>Zephyrm Bioscience&rsquo;s losses have increased by more than two times year-on-year to 237 million yuan in the first half of 2024</li>
<li>The company has only four products, with only one product in Phase II clinical trials, far from commercialization</li>
</ul>
By Fai Pui
Stock markets in the mainland China and Hong Kong have once again become active under a series of policy packages to rescue the market. More and more companies are planning go public on the Hong Kong Stock Exchange for fund raising in the fourth quarter, hoping to obtain a higher valuation amid this stock market frenzy.
Founded in 2017,&nbsp;Zephyrm Bioscience Ltd., a young stem-cell drug researcher, developer and producer, filed for a&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2024/106833/documents/sehk24093002559.pdf">listing application</a>&nbsp;to the Hong Kong Stock Exchange on the last day of September, with CICC as the exclusive sponsor.
Like most biotech companies at their early stages, Zephyrm currently has no commercialized product and thus no revenue. Instead, according to the prospectus, the company has been knee deep in losses pile-up, rising from about 173 million yuan ($24.4 million) in 2022 to 196 million yuan in 2023, and to whopping 237 million yuan in the first half of 2024, which has surged 210% over the same period in 2023.
The sharp increase in losses was mainly driven by the skyrocketing administrative expenses in the first half of 2024, from 18.37 million yuan in 2023 to 143 million yuan. Notably, 114 million yuan of share-based compensation expenses, which had not been incurred in the past two years, is also included in the administrative cost. Meanwhile, R&amp;D is the second biggest cause of its mounting losses. While the relevant spending has increased from 66.31 million yuan in 2022, to 103 million yuan in 2023, now it has already been up to 58.52 million yuan in the first half of 2024, marking a surprising increase of 71.4% over the same period last year.
Mainly engaging in the development of innovative cell therapy products derived from pluripotent stem cells (PSC) that can treat a variety of diseases, Zephyrm is one of the first companies in China and even the world to develop PSC-derived cell therapy products. According to Frost &amp; Sullivan, the company is one of the first in China to be approved for an investigational new drug (IND) application for PSC-derived cell therapy, and the only company in China with multiple PSC-derived cell therapy assets in Phase II clinical trials.
According to the prospectus, Zephyrm&rsquo;s current product portfolio includes its core product ZH901 and its major products ZH903, ZH902 and ZH906. ZH901 is a M-cell therapy product that is being studied for the treatment of injuries and inflammations as well as degenerative diseases. Its clinical development in China for various indications has entered phase two. About 100 patients have been treated with ZH901 through intravenous infusion or intra-articular administration in the knee joint in multiple clinical trials, but none of them experienced serious adverse effects.
However, all these other three products are still in the early clinical stage. ZH903 is a mDAP cell therapy product for the treatment of Parkinson&rsquo;s disease; ZH902 is a RPE cell therapy product for the treatment of dry AMD to improve patients&rsquo; impaired vision; and ZH906 is a CEnC therapy product for the treatment of corneal endothelial dysfunction.
In addition, Zephyrm has developed a PSC-derived cell therapy products development platform (PROF), which comprises three independent platforms, namely, Pluripotent Stem Cell Seed Platform (PROF-seed), Vital Functional Cell Development Platform (PROF-function), and Formulation Optimization Platform (PROF-formulator). This unique set of integrated technology platforms is designed to help the company develop products more effectively.
In order to support future commercialization, Zephyrm has established a factory in Beijing with a total construction area of approximately 2,380 square meters. It will be able to produce approximately 35,000 injections of cell therapy products annually to support the company&rsquo;s clinical development and early commercialization. The company is also planning to establish a manufacturing plant in Zhongshan City, Guangdong Province, with a total construction area of approximately 150,000 square meters and an estimated annual production capacity of approximately 500,000 injections of cell therapy products to support commercial production. The new expansion projects will officially commence production in 2030.
Therefore, it is not surprising to know the funds raised in the listing, if succeeded, would be used for the factory in Zhongshan City, and for product R&amp;D and clinical research.
<h3>Only 78 Million Yuan Of Cash In Hand</h3>
However, the nearly empty pocket for R&amp;D is the biggest reason for Zephyrm&rsquo;s enthusiasm over IPO. As of the end of June 2024, it only has 78.26 million yuan in cash and cash equivalents, a significant decrease of 53% compared to the end of 2023. However, on the one hand, its R&amp;D expenditure throughout the year of 2023 already reached 103 million yuan, already amounted to 58.52 million yuan in the first half of 2024. On the other hand, this biotech company still has no commercial products or obtain any government subsidies in the first half of 2024. That means turning to the capital market for funds to support R&amp;D becomes the only way to go.
In addition, early investors are also eager to cash out. According to the prospectus, the company launched an angel round of financing in 2019, receiving funds from investors including Zhongke Chuangxing Hard Technology, Zhonghe Tiancheng Entrepreneur Management, Xi&rsquo;an Yingshi Fukun Biotechnology and Shandong Haoyang Biological Engineering. Back then, it raised 150 million yuan at the cost per share of 3.87 yuan.
One year later, it carried out the A-round financing with the cost per share increasing to 8.3 yuan, pocketing another 160 million yuan from investors such as Beijing Guoke Dingzhi Equity Investment, Beijing Yuanqing Bencao Equity Investment and Beijing Yingshi Biotechnology. Then it conducted another round of financing in the B, B+, and B++ rounds at 9.38 yuan per share between 2022 to 2024. Investors include Beijing Yingsheng Fukun Biotechnology, Jiaxing Chenyue Equity Investment Partnership and Beijing Yingshi Biotechnology. The three rounds of financing have raised 656 million yuan in total for Zephyrm, and all early investors are in a 180-day lock-up period.
With about 20 million yuan invested for 0.89% shares by Beijing Xietai Management Partnership, Zephyrm should be worth about 2.25 billion yuan. However, Hong Kong Stock Exchange is no short of biotechnology stocks. Investing in biotechnology companies is basically placing a bet on whether the company&rsquo;s products can eventually pass clinical trials and successfully enter commercialization.
Now the show is finally heating up again in Hong Kong, and the IPO is filled with hustling and bustling again. The share price of&nbsp;TYK Medicines&nbsp;(2410.HK), a biotech stock listed in August, has risen by about 150% so far. If Zephyrm can pass the listing hearing, investors chasing short-term profits may flock in to the subscription.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Asia

Biotech

Markets

General

Increasing Losses Prompt Zephyrm Bioscience To Seek Funds Through IPO

Morgan Stanley analyst Michael Cyprys maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Equal-Weight and raises the price target from $111 to $137.

Morgan Stanley Maintains Equal-Weight on Apollo Global Management, Raises Price Target to $137

Momentum trading involves buying rising stocks with the idea that they will continue rising. While reminiscent of the greater fools theory, momentum trading is more than buying high and selling high. Good momentum trades combine factors that help ensure the market is bullish and capable of continuing the uptrend with catalysts to drive the market even higher.&nbsp;
The stocks in this article do just that: they combine numerous variables, including fundamental quality, an outlook for growth, analysts and institutional support, and catalysts for additional upside. A starting place to find such stocks in the future? MarketBeat&#39;s list of Most Upgraded Stocks and the Momentum Alerts feature.
<h2>Meta Platforms to Hit $660 in 2025</h2>
Meta Platforms&nbsp;has been a hot momentum trade for the last two years. The stock hit bottom in 2023, and the rebound was accelerated by the &quot;year of efficiency&quot; and then AI-enabled improvements in user, ad display, and revenue-per-ad metrics. The net result is a resurgence in growth, sustained in the high double-digits in 2024 expected to continue in 2025. Highlights from 2024 suggest the 2025 consensus estimates are low, providing a potential tailwind for the market in the form of outperformance and analyst upgrades to revenue and earnings targets.&nbsp;
Analysts support this market. The action in Q3 lifted the stock into the #1 position on MarketBeat&#39;s list of Most Upgraded Stocks, with 35 positive revisions in the 90 days leading into October. The analysts rate the stock as a Moderate Buy and have aggressively increased their stock price targets.&nbsp;
The consensus target assumes fair value near the early October highs but has been up by nearly 100% in the last 12 months and is rising. The freshest targets include initiated coverage by Pivotal Research, which put the stock price at $780 compared to the $600 consensus figure. Because most targets issued since mid-summer are at or above the consensus, Meta will likely continue to move higher in calendar Q4.&nbsp;
The next visible catalyst for Meta Platforms is the FQ3 earnings report due at the end of the month. The analysts have set the bar high with revisions, but the consensus may still underestimate reality, expecting a sequential slowdown in YoY growth. Meta Platforms has outpaced top and bottom-line consensus forecasts for six consecutive quarters.
<img alt="META stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009095008_chart-meta-1092024.png" style="height:423px; width:917px" />
<h2>Palo Alto Networks: Growth, Cash Flow, Analysts, and Nancy Pelosi Support This Stock</h2>
Analysts&#39; activity lifted Palo Alto Networks (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panw#NASDAQ">PANW</a>) into the 2nd position on the list of Most Upgraded Stocks in late summer. The activity includes numerous revisions and an initiated coverage, pegging the stock at Moderate Buy with a high likelihood of advancing above the consensus price target. The consensus implies fair value near the current levels, but the revisions trend leads to the high-end range with high conviction. More than 80% of the targets issued in calendar Q3 are above consensus, with most suggesting a minimum of 5% upside from the critical resistance target.&nbsp;
The reason analysts are bullish is the company results. Sentiment dimmed when the plaformization plan was announced, but the results since have been better than expected. They reveal underlying business strength and a faster-than-expected impact from the shift, expected to drive long-term growth and wider margins. The next visible catalyst is the FQ1 results due in mid-November. Analysts are raising the bar with revisions, but consensus underestimates business strength, expecting a sequential decline in revenue and earnings.&nbsp;
<img alt="Palo Alto Networks PANW stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009095016_chart-panw-01092024.png" style="height:423px; width:917px" />
<h2>Oracle: The New Go-To Source for Enterprise Cloud Database</h2>
Oracle&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) multi-year to cloud-based software services kicked into high gear this year. The company has emerged as a leader in AI infrastructure and services, as evidenced by a deal with Amazon. The Amazon deal will embed Oracle&#39;s enterprise-quality services into its cloud, making it the leading choice among the three dominant cloud hyperscalers.&nbsp;
Results in 2024 drive an analyst upgrade cycle, and the revisions are robust. The activity resulted in Oracle shooting up the rankings, breaking into the top ten with 6th position in early October. The consensus target lags the market but supports the price action due to the revision trend. The consensus is up 35% since October 2023, and revisions lead to the high-end range above $200, a 15% upside for investors. The next visible catalyst is the FQ2 results due in early December, although results from other critical AI players may also drive the market.<img alt="Oracle ORCL stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009101502_chart-orcl-1092024.png?1728486902436" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-momentum-trades-for-october-with-ample-upside-ahead/">3 Momentum Trades for October&nbsp;With Ample Upside Ahead</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Tech

Trading Ideas

ORCL

PANW

3 Momentum Trades for October With Ample Upside Ahead

KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>, TSXV:<a class="ticker" href="https://www.benzinga.com/stock/KWE#TSXV">KWE</a>) ("KWESST" or the "Company") announces that its board of directors (the "Board") has authorized a plan to proceed with a consolidation of its outstanding common shares (each, a "Share") on the basis of ten (10) pre-consolidation Shares for each one (1) post-consolidation Share (the "Consolidation"). The Consolidation is subject to approval of the TSX Venture Exchange (the "Exchange"). The Company believes that the Consolidation is in the best interests of shareholders as it will allow the Company to ensure continued compliance with the NASDAQ Stock Market minimum bid price requirements. Accordingly, the Company opted not to hold its special meeting of shareholders pursuant to which it was seeking a consolidation of its Shares on a greater basis.
As at the date hereof, there are a total of 15,791,742 Shares issued and outstanding. Assuming no other change to the issued and outstanding Shares, if the Consolidation is put into effect, a total of 1,579,174 Shares, subject to adjustments for rounding, would be issued and outstanding.

Stock Split

TSXV:KWE

KWESST Micro Systems Announces Proposed 10-For-1 Share Consolidation

Lake Street analyst Rob Brown maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and raises the price target from $7 to $11.

APLD

Lake Street Maintains Buy on Applied Digital, Raises Price Target to $11

AMD Executive Says Expects Data Center AI Market To Grow To $500B In 2028

WIIM

FIVN

Five9 shares are trading higher after the company announced it expanded its global presence through new data centers in Delhi and Mumbai. Additionally, the company secured a DOT certification to offer access and long-distance services in India.

Lake Street analyst Robert Brown maintains LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) with a Buy and lowers the price target from $9 to $6.

LIQT

Lake Street Maintains Buy on LiqTech Intl, Lowers Price Target to $6

Cinemark Holdings shares are trading higher after Roth MKM and Wells Fargo raised their respective price targets on the stock.

Looking at gold, it remains in a very strong uptrend, though it has paused due to the impressive recovery in the US dollar. The dollar could continue to see more upside, especially given that inflation came in a bit stickier at 2.4% rather than the expected 2.3%. However, even if the dollar strengthens after the next pullback, there's still a chance that gold will resume its uptrend. Remember, if inflation remains elevated and doesn't trend downward, gold could be seen as an inflation hedge. Additionally, gold tends to perform well during times of geopolitical risk, like the current issues in the Middle East.
In terms of the wave count, we're seeing a very nice three-wave retracement in gold back to the 2600 level, which is a key level from mid-September when the Fed cut rates by 50 basis points. This level could now serve as a good area for the next swing to the upside. Ideally, this push higher could occur in the fifth wave, especially if the price breaks above the 2635 resistance, markets as bullish level, which could open the door to 2700.
On the downside, the channel support is critical, but the most important level for identifying a potential top would be a break below 2532. Only then could we say the top is in place, as this would invalidate the uptrend based on Elliott Wave rules, which dictate that wave 4 must not fall into the territory of wave 1.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="800" height="751" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png" alt="" class="wp-image-2172" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-300x282.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-768x721.png 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
Trade Well,
Grega Horvat
Forex Analytix

Commodities

Gold Has More Upside After This Pullback

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are currently competing for a seat at an elite table: The <a href="https://www.benzinga.com/news/24/07/39674237/tsmcs-market-cap-hits-1-trillion-whats-going-on-with-the-stock">exclusive trillion-dollar club</a>. 
Taiwan Semiconductor&#8217;s market cap first crossed the <a href="https://www.benzinga.com/news/24/07/39733017/taiwan-semiconductor-joins-the-trillion-dollar-club-surpassing-tesla-report">trillion-dollar threshold in July</a>. It has since contracted to roughly $820 billion — a stone&#8217;s throw away from Broadcom&#8217;s $867 billion. 
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) are among the club&#8217;s current members after their market caps exceeded a trillion dollars, fueled <a href="https://www.benzinga.com/topic/artificial-intelligence">by AI advancements</a>.
With TSM and Broadcom both driving critical innovations in AI semiconductors, we ask: Which company&#8217;s market cap will attain nine zeros next?
<h2 class="wp-block-heading">TSMC: AI-Driven Chipmaker Poised For Growth</h2>
Taiwan Semiconductor stands as the world's largest contract chipmaker, leading the market with its 3nm and 5nm technology. These chips are integral for AI workloads, fueling AI giants like Nvidia and Apple.
This has propelled TSM's stock by over 83.3% year-to-date and 105.39% in the past year.
Analysts from Needham and Susquehanna maintain Overweight ratings, with an average price target of $236.67, implying 27.15% upside. A price at that level would push TSM's market cap to over $1.23 trillion, positioning it to re-join the trillion-dollar club.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png" alt="" class="wp-image-589674" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, TSMC is also in a bullish trend with buying pressure across its eight, 20, 50 and 200-day moving averages, all signaling continued upward momentum. 
TSM&#8217;s stock currently trades at $186.33, supported by a simple moving average, or SMA, (50-day) of $170.55 and a SMA (200-day) of $149.54, indicating positive technical indicators.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41245350/nvidia-poised-to-overtake-apple-as-worlds-most-valuable-company-how-much-jensen-huangs-company-n">Nvidia Poised To Overtake Apple As World&#8217;s Most Valuable Company</a>
<h2 class="wp-block-heading">Broadcom: AI Infrastructure Play With Solid Momentum</h2>
Broadcom is capitalizing on the AI boom through its extensive semiconductor solutions for data centers, networking infrastructure, and real-time analytics. 
Its stock is up 69.28% year-to-date and 114.05% in the past year. Despite bullish ratings, its projected upside falls short of TSM. Analysts from Cantor Fitzgerald, Truist Securities, and UBS see AVGO reaching $200, implying an 8.80% upside, which would push its market cap to $934 billion.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png" alt="" class="wp-image-589675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, Broadcom is also trending positively, with its current price of $184.40 supported by moving averages, such as its 50-day SMA of $161.82 and 200-day SMA of $142.55. However, it still lags behind TSM's stronger growth trajectory.
<h2 class="wp-block-heading">TSMC Could Outpace Broadcom In the Trillion-Dollar Race</h2>
While both stocks are positioned to benefit from AI, TSMC has the edge, with superior technical indicators and greater market cap potential. 
With an imminent leap toward $1.23 trillion in market cap if it meets analysts&#8217; upside potential, TSM appears more likely to reach the trillion-dollar club before Broadcom.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41271262/broadcom-micron-traders-get-new-tools-with-direxions-latest-leveraged-bull-and-bear-etfs">Broadcom, Micron Traders Get New Tools With Direxion&#8217;s Latest Leveraged Bull And Bear ETFs</a></li>
</ul>

Technicals

AAPL

AVGO

MSFT

NVDA

Taiwan Semiconductor Vs. Broadcom: Who Will Be The Next Trillion-Dollar AI Giant?

Illumina introduces new DNA sequencing instruments, but Street unimpressed

10x Genomics plummets 27% after hours following Q3 preliminary earnings miss

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), 10x Genomic...

Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), 10x Genomics (TXG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 10x Genomics (TXG – Research Report), Dyne Therapeut...

Analysts' Top Healthcare Picks: 10x Genomics (TXG), Dyne Therapeutics (DYN)

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from ...

10x Genomics: Hold Rating Amidst Q3 Revenue Shortfall and Growth Uncertainty

Biggest stock movers Thursday: GXO, TXG, and more

Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on 10x Genomics (TXG – Research Report). The associated price target ...

Buy Rating Affirmed for 10x Genomics Amidst Long-Term Growth Potential Despite Short-Term Challenges

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target ...

Stifel Nicolaus Sticks to Their Buy Rating for 10x Genomics (TXG)

TD Cowen analyst Daniel Brennan maintained a Hold rating on 10x Genomics (TXG – Research Report) today and set a price target of $20.00. The compan...

TD Cowen Sticks to Its Hold Rating for 10x Genomics (TXG)

Biggest stock movers Thursday: TLRY, GXO, TXG, and more

ALNY

CRWD

EVGO

FSLR

ILMN

RLAY

TLRY

Press Releases

New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies

10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases

10x Genomics Reports Second Quarter 2024 Financial Results

10x Genomics Announces Senior Leadership Changes

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Stephens & Co.

Canaccord Genuity

Leerink Partners

Morgan Stanley

10x Genomics shares are trading lower after the company guided Q3 preliminary revenue of ~$151.7 million, down 1% year over year.

Comments

10x Genomics

Actualités

Dernières nouvelles pour 10x Genomics (NASDAQ:TXG) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL